Jounce Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, Feb...
February 21 2020 - 1:25PM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will report fourth quarter and full year 2019 financial results and
provide a corporate update before market open on Thursday, February
27, 2020. Jounce Therapeutics' management team will host a live
conference call and webcast at 8:00 a.m. ET.
Conference Call and WebcastTo access the
conference call, please dial (866) 916-3380 (domestic) or (210)
874-7772 (international) and refer to conference ID 7889239. The
live webcast can be accessed under "Events & Presentations" in
the Investors and Media section of the company's website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s website approximately two hours after
the call and will be available for 30 days thereafter.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
has three development-stage programs, two of which are
clinical-stage, vopratelimab, a monoclonal antibody that binds to
and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for
potential combination use with Jounce’s broader pipeline.
Vopratelimab is currently being assessed in a Phase 2 clinical
trial, EMERGE, and a biomarker trial using TISvopra for patient
selection, SELECT, to assess vopratelimab in combination with
JTX-4014 will be initiated mid year 2020. The next development
candidate to emerge from Jounce’s Translational Science Platform is
JTX-1811, a monoclonal antibody designed to selectively deplete T
regulatory cells in the tumor microenvironment. JTX-1811 is
currently in IND-enabling activities. In addition, Jounce has
exclusively licensed worldwide rights to JTX-8064, a LILRB2
receptor antagonist, to Celgene Corporation, a wholly-owned
subsidiary of Bristol-Myers Squibb Company. For more information,
please visit www.jouncetx.com.
Investor and Media Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024